Despite failing its PhII test, Xenon sees future for major depression drug

Ayisha Sharma

News Reporter

Xenon Pharmaceuticals’ major depressive disorder drug candidate didn’t reach statistical significance versus placebo in the primary endpoint of a mid-stage trial, but the Canadian biotech …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Despite failing its PhII test, Xenon sees future for major depression drug

Ayisha Sharma

News Reporter

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

FDA inspectors discover trucks carrying torn-up records leaving Indian generics factory

Aligos’ trial for oral MASH treatment succeeds, but placebo group shows odd trend

Lasker Award goes to three scientists who pioneered research behind GLP-1 drugs

Roche outlines commercial manufacturing strategy for GLP-1/GIP assets

Exclusive: Flagship-backed Valo Health loses interim CEO ahead of key Phase 2 readout

Breaking down silos with a new quantitative approach to drug development

De­spite fail­ing its PhII test, Xenon sees fu­ture for ma­jor de­pres­sion drug

News Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Despite failing its PhII test, Xenon sees future for major depression drug